Tumor immunotherapy: making an immortal army

Manipulation of cell renewal pathways creates T memory stem cells that can generate a sustained and targeted immune response. These findings have broad implications for vaccine development and immunotherapy (pages 808–813).

Access options

Rent or Buy article

Get time limited or full article access on ReadCube.


All prices are NET prices.

Figure 1: Same pathway, different outcomes? During hematopoiesis in the bone marrow, the Wnt–β-catenin pathway limits the proliferation and differentiation of hematopoietic stem cells (HSCs) so that division can regenerate HSCs in addition to the multipotent stem cells (MSCs) that give rise to lymphoid progenitor cells (LPCs) and myeloid progenitor stem cells (MPCs).


  1. 1

    Herodotus. Histories (de Selincourt, A., trans.) edn. 11 (Penguin, London, 1972).

  2. 2

    Gattinoni, L. et al. Nat. Med. 15, 808–813 (2009).

  3. 3

    Berke, G. Annu. Rev. Immunol. 12, 735–773 (1994).

  4. 4

    Surh, C.D. & Sprent, J. Immunity 29, 848–862 (2008).

  5. 5

    Croce, J.C. & McClay, D.R. Methods Mol. Biol. 469, 3–18 (2008).

  6. 6

    Mosimann, C., Hausmann, G. & Basler, K. Nat. Rev. Mol. Cell Biol. 10, 276–286 (2009).

  7. 7

    Malhotra, S. & Kincade, P.W. Cell Stem Cell 4, 27–36 (2009).

  8. 8

    Stemberger, C. et al. Semin. Immunol. 21, 62–68 (2009).

Download references

Author information

Correspondence to Stephen P. Schoenberger.

Rights and permissions

Reprints and Permissions

About this article

Cite this article

Koehn, B., Schoenberger, S. Tumor immunotherapy: making an immortal army. Nat Med 15, 731–732 (2009). https://doi.org/10.1038/nm0709-731

Download citation

Further reading